title: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
abstract: OBJECTIVE
  We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer.
  
  
  METHODS
  A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in combination with carboplatin.
  
  
  RESULTS
  The response rate was 17% in the paclitaxel arm and 30% in the carboplatin-paclitaxel arm (P < .0001). Median failure-free survival was 2.5 months in the paclitaxel arm and 4.6 months in the carboplatin-paclitaxel arm (P = .0002). Median survival times were 6.7 months (95% CI, 5.8 to 7.8) and 8.8 months (95% CI, 8.0 to 9.9), and 1-year survival rates were 32% (95% CI, 27% to 38%), and 37% (95% CI, 32% to 43%), respectively. The overall survival distributions were not statistically different: hazard ratio = 0.91 (95% CI, 0.77 to 1.17; P = .25). Hematological toxicity and nausea were more frequent in the combination arm, but febrile neutropenia and toxic deaths were equally low in both arms. There was no significant survival difference in elderly patients. Performance status 2 patients treated with combination chemotherapy had a better survival rate than those treated with single-agent therapy (P = .019).
  
  
  CONCLUSIONS
  Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy, but there was no statistically significant difference in the primary end point of overall survival. The results in elderly patients were similar to younger patients. Performance status 2 patients had a superior outcome when treated with combination chemotherapy.
authors.affiliation: The Mount Sinai Comprehensive Cancer Center, 4306 Alton Rd, Miami Beach, FL, USA. Rlilenba@salick.com
authors.forename: Rogerio C
authors.initials: RC
authors.lastname: Lilenbaum
authors.forename: James E
authors.initials: JE
authors.lastname: Herndon
authors.forename: Marcy A
authors.initials: MA
authors.lastname: List
authors.forename: Chris
authors.initials: C
authors.lastname: Desch
authors.forename: Dorothy M
authors.initials: DM
authors.lastname: Watson
authors.forename: Antonius A
authors.initials: AA
authors.lastname: Miller
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Graziano
authors.forename: Michael C
authors.initials: MC
authors.lastname: Perry
authors.forename: Wayne
authors.initials: W
authors.lastname: Saville
authors.forename: Philippe
authors.initials: P
authors.lastname: Chahinian
authors.forename: Jane C
authors.initials: JC
authors.lastname: Weeks
authors.forename: Jimmie C
authors.initials: JC
authors.lastname: Holland
authors.forename: Mark R
authors.initials: MR
authors.lastname: Green
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel